Thomas M. Moon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thomas M. Moon has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Wolfgang R. Dostmann
Department of Pharmacology, College of Medicine, University of Vermont, Burlington, VT 05405, USA
4 shared publications Jessica L. Sheehe
From the Department of Pharmacology, Larner College of Medicine, and
3 shared publicationsAlexander T. Piala
Department of Biophysics, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
2 shared publicationsBrent W. Osborne
Department of Pharmacology, College of Medicine, The University of Vermont, 89 Beaumont Avenue, Burlington, VT 05405, USA
2 shared publicationsCharlene Desbonnet
The ‖Departments of Medicine and Microbiology and Immunology, Warren Alpert School of Medicine of Brown University, Providence, Rhode Island 02903
2 shared publications- Elizabeth J. Goldsmith
Department of Biophysics, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-8816, United States
2 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Springer Nature in Nature Communications
Energy-guided combinatorial co-optimization of antibody affinity and stability
- 5 November 2026
- Published by Springer Nature in Nature Communications
Open AccessEnergy-guided combinatorial co-optimization of antibody affinity and stability
- Open Access
- 24 January 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2451296
Engineered ipilimumab variants that bind human and mouse CTLA-4
Testing of candidate monoclonal antibody therapeutics in preclinical models is an essential step in drug development. Identification of antibody therapeutic candidates that bind their human targets and cross-react to mouse orthologs is often challenging, especially for targets with low sequence homology. In such cases, surrogate antibodies that bind mouse orthologs must be used. The antibody 9D9, which binds mouse CTLA-4, is a commonly used surrogate for CTLA-4 checkpoint blockade studies in mouse cancer models. In this work, we reveal that 9D9 has significant biophysical dissimilarities to therapeutic CTLA-4 antibodies. The 9D9-mCTLA4 complex crystal structure was determined and shows that the surrogate antibody binds an epitope distinct from ipilimumab and tremelimumab. In addition, while ipilimumab has pH-independent binding to hCTLA-4, 9D9 loses binding to mCTLA-4 at physiologically relevant acidic pH ranges. We used phage and yeast display to engineer ipilimumab to bind mouse CTLA-4 with single-digit nM affinity from an initial state with no apparent binding. The engineered variants showed pH-independent and cross-reactive binding to both mouse and human CTLA-4. Crystal structures of a variant in complex with both mouse and human CTLA-4 confirmed that it targets an equivalent epitope as ipilimumab. These cross-reactive ipilimumab variants may facilitate improved translatability and future mechanism-of-action studies for anti-CTLA-4 targeting in murine models.
- 24 January 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2451296
Open AccessEngineered ipilimumab variants that bind human and mouse CTLA-4
Testing of candidate monoclonal antibody therapeutics in preclinical models is an essential step in drug development. Identification of antibody therapeutic candidates that bind their human targets and cross-react to mouse orthologs is often challenging, especially for targets with low sequence homology. In such cases, surrogate antibodies that bind mouse orthologs must be used. The antibody 9D9, which binds mouse CTLA-4, is a commonly used surrogate for CTLA-4 checkpoint blockade studies in mouse cancer models. In this work, we reveal that 9D9 has significant biophysical dissimilarities to therapeutic CTLA-4 antibodies. The 9D9-mCTLA4 complex crystal structure was determined and shows that the surrogate antibody binds an epitope distinct from ipilimumab and tremelimumab. In addition, while ipilimumab has pH-independent binding to hCTLA-4, 9D9 loses binding to mCTLA-4 at physiologically relevant acidic pH ranges. We used phage and yeast display to engineer ipilimumab to bind mouse CTLA-4 with single-digit nM affinity from an initial state with no apparent binding. The engineered variants showed pH-independent and cross-reactive binding to both mouse and human CTLA-4. Crystal structures of a variant in complex with both mouse and human CTLA-4 confirmed that it targets an equivalent epitope as ipilimumab. These cross-reactive ipilimumab variants may facilitate improved translatability and future mechanism-of-action studies for anti-CTLA-4 targeting in murine models.
- 30 September 2019
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 58 (41) , 4183-4194
Retinoic Acid Binding Leads to CRABP2 Rigidification and Dimerization
Cellular retinoic acid-binding protein 2 (CRABP2) delivers all-trans retinoic acid (atRA) to Retinoic Acid Receptors (RARs), allowing for the activation of specific gene transcription. The structural similarities between free and atRA-bound CRABP2 raise the question of how atRA binding occurs and how the atRA:CRABP2 complex is recognized by downstream binding partners. Thus, in order to gain insights into these questions, we conducted a detailed atRA-CRABP2 interaction study using Nuclear Magnetic Resonance (NMR) spectroscopy. The data showed that free CRABP2 displays widespread intermediate timescale dynamics that is effectively suppressed upon atRA binding. This effect is mirrored by the fast-timescale dynamics of CRABP2. Unexpectedly, CRABP2 rigidification in response to atRA binding leads to the stabilization of a homodimerization interface, which encompasses residues located on helix α2 and the βC-βD loop as well as residues on strands βI-βA and the βH-βI loop. Critically, this rigidification also affects CRABP2’s nuclear localization signal (NLS) and RAR-binding motif, suggesting that the loss of conformational entropy upon atRA binding may be the key for the diverse cellular functions of CRABP2.
- 30 September 2019
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 58 (41) , 4183-4194
Retinoic Acid Binding Leads to CRABP2 Rigidification and Dimerization
Cellular retinoic acid-binding protein 2 (CRABP2) delivers all-trans retinoic acid (atRA) to Retinoic Acid Receptors (RARs), allowing for the activation of specific gene transcription. The structural similarities between free and atRA-bound CRABP2 raise the question of how atRA binding occurs and how the atRA:CRABP2 complex is recognized by downstream binding partners. Thus, in order to gain insights into these questions, we conducted a detailed atRA-CRABP2 interaction study using Nuclear Magnetic Resonance (NMR) spectroscopy. The data showed that free CRABP2 displays widespread intermediate timescale dynamics that is effectively suppressed upon atRA binding. This effect is mirrored by the fast-timescale dynamics of CRABP2. Unexpectedly, CRABP2 rigidification in response to atRA binding leads to the stabilization of a homodimerization interface, which encompasses residues located on helix α2 and the βC-βD loop as well as residues on strands βI-βA and the βH-βI loop. Critically, this rigidification also affects CRABP2’s nuclear localization signal (NLS) and RAR-binding motif, suggesting that the loss of conformational entropy upon atRA binding may be the key for the diverse cellular functions of CRABP2.
- 23 September 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (41) , 20472-20481
SDS22 selectively recognizes and traps metal-deficient inactive PP1
The metalloenzyme protein phosphatase 1 (PP1), which is responsible for ≥50% of all dephosphorylation reactions, is regulated by scores of regulatory proteins, including the highly conserved SDS22 protein. SDS22 has numerous diverse functions, surprisingly acting as both a PP1 inhibitor and as an activator. Here, we integrate cellular, biophysical, and crystallographic studies to address this conundrum. We discovered that SDS22 selectively binds a unique conformation of PP1 that contains a single metal (M2) at its active site, i.e., SDS22 traps metal-deficient inactive PP1. Furthermore, we showed that SDS22 dissociation is accompanied by a second metal (M1) being loaded into PP1, as free metal cannot dissociate the complex and M1-deficient mutants remain constitutively trapped by SDS22. Together, our findings reveal that M1 metal loading and loss are essential for PP1 regulation in cells, which has broad implications for PP1 maturation, activity, and holoenzyme subunit exchange.
- 23 September 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (41) , 20472-20481
SDS22 selectively recognizes and traps metal-deficient inactive PP1
The metalloenzyme protein phosphatase 1 (PP1), which is responsible for ≥50% of all dephosphorylation reactions, is regulated by scores of regulatory proteins, including the highly conserved SDS22 protein. SDS22 has numerous diverse functions, surprisingly acting as both a PP1 inhibitor and as an activator. Here, we integrate cellular, biophysical, and crystallographic studies to address this conundrum. We discovered that SDS22 selectively binds a unique conformation of PP1 that contains a single metal (M2) at its active site, i.e., SDS22 traps metal-deficient inactive PP1. Furthermore, we showed that SDS22 dissociation is accompanied by a second metal (M1) being loaded into PP1, as free metal cannot dissociate the complex and M1-deficient mutants remain constitutively trapped by SDS22. Together, our findings reveal that M1 metal loading and loss are essential for PP1 regulation in cells, which has broad implications for PP1 maturation, activity, and holoenzyme subunit exchange.
- Open Access
- 1 November 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (48) , 18574-18584
The structures of penicillin-binding protein 4 (PBP4) and PBP5 from Enterococci provide structural insights into β-lactam resistance
- 1 November 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (48) , 18574-18584
Open AccessThe structures of penicillin-binding protein 4 (PBP4) and PBP5 from Enterococci provide structural insights into β-lactam resistance
- Open Access
- 1 October 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (43) , 16791-16802
Oxidation of cysteine 117 stimulates constitutive activation of the type Iα cGMP-dependent protein kinase
- 1 October 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (43) , 16791-16802
Open AccessOxidation of cysteine 117 stimulates constitutive activation of the type Iα cGMP-dependent protein kinase
- Open Access
- 2 May 2018
- Published by American Society for Microbiology in mBio
- Vol. 9 (2) , e00361-18
Structural and Regulatory Changes in PBP4 Trigger Decreased β-Lactam Susceptibility in Enterococcus faecalis
Enterococcus faecalis strains resistant to penicillin and ampicillin are rare and have been associated with increases in quantities of low-affinity penicillin-binding protein 4 (PBP4) or with amino acid substitutions in PBP4. We report an E. faecalis strain (LS4828) isolated from a prosthetic knee joint that was subjected to long-term exposure to aminopenicillins. Subsequent cultures yielded E. faecalis with MICs of penicillins and carbapenems higher than those for wild-type strain E. faecalis JH2-2. Sequence analysis of the pbp4 gene of LS4828 compared to that of JH2-2 revealed two point mutations with amino acid substitutions (V223I, A617T) and deletion of an adenine from the region upstream of the predicted pbp4 −35 promoter sequence (UP region). Purified PBP4 from LS4828 exhibited less affinity for Bocillin FL than did PBP4 from JH2-2, which was recapitulated by purified PBP4 containing only the A617T mutation. Differential scanning fluorimetry studies showed that the LS4828 and A617T variants are destabilized compared to wild-type PBP4. Further, reverse transcription-PCR indicated increased transcription of pbp4 in LS4828 and Western blot analysis with polyclonal PBP4 antibody revealed greater quantities of PBP4 in LS4828 than in JH2-2 lysates and membrane preparations. Placing the promoter regions from LS4828 or JH2-2 upstream of a green fluorescent protein reporter gene confirmed that the adenine deletion was associated with increased transcription. Together, these data suggest that the reduced susceptibility to β-lactam antibiotics observed in E. faecalis LS4828 results from a combination of both increased expression and remodeling of the active site, resulting in reduced affinity for penicillins and carbapenems. IMPORTANCE Enterococcus faecalis is an important cause of community-acquired and nosocomial infections and creates therapeutic dilemmas because of its frequent resistance to several classes of antibiotics. We report an E. faecalis strain with decreased ampicillin and imipenem susceptibility isolated after prolonged courses of aminopenicillin therapy for a prosthetic joint infection. Its reduced susceptibility is attributable to a combination of increased quantities of low-affinity PBP4 and an amino acid substitution in proximity to the active site that destabilizes the protein. Our findings provide a cautionary tale for clinicians who elect to “suppress” infections in prosthetic joints and offer novel insights into the interaction of β-lactam antibiotics with low-affinity PBP4. These insights will help inform future efforts to develop therapeutics capable of inhibiting clinical enterococcal strains.
- 2 May 2018
- Published by American Society for Microbiology in mBio
- Vol. 9 (2) , e00361-18
Open AccessStructural and Regulatory Changes in PBP4 Trigger Decreased β-Lactam Susceptibility in Enterococcus faecalis
Enterococcus faecalis strains resistant to penicillin and ampicillin are rare and have been associated with increases in quantities of low-affinity penicillin-binding protein 4 (PBP4) or with amino acid substitutions in PBP4. We report an E. faecalis strain (LS4828) isolated from a prosthetic knee joint that was subjected to long-term exposure to aminopenicillins. Subsequent cultures yielded E. faecalis with MICs of penicillins and carbapenems higher than those for wild-type strain E. faecalis JH2-2. Sequence analysis of the pbp4 gene of LS4828 compared to that of JH2-2 revealed two point mutations with amino acid substitutions (V223I, A617T) and deletion of an adenine from the region upstream of the predicted pbp4 −35 promoter sequence (UP region). Purified PBP4 from LS4828 exhibited less affinity for Bocillin FL than did PBP4 from JH2-2, which was recapitulated by purified PBP4 containing only the A617T mutation. Differential scanning fluorimetry studies showed that the LS4828 and A617T variants are destabilized compared to wild-type PBP4. Further, reverse transcription-PCR indicated increased transcription of pbp4 in LS4828 and Western blot analysis with polyclonal PBP4 antibody revealed greater quantities of PBP4 in LS4828 than in JH2-2 lysates and membrane preparations. Placing the promoter regions from LS4828 or JH2-2 upstream of a green fluorescent protein reporter gene confirmed that the adenine deletion was associated with increased transcription. Together, these data suggest that the reduced susceptibility to β-lactam antibiotics observed in E. faecalis LS4828 results from a combination of both increased expression and remodeling of the active site, resulting in reduced affinity for penicillins and carbapenems. IMPORTANCE Enterococcus faecalis is an important cause of community-acquired and nosocomial infections and creates therapeutic dilemmas because of its frequent resistance to several classes of antibiotics. We report an E. faecalis strain with decreased ampicillin and imipenem susceptibility isolated after prolonged courses of aminopenicillin therapy for a prosthetic joint infection. Its reduced susceptibility is attributable to a combination of increased quantities of low-affinity PBP4 and an amino acid substitution in proximity to the active site that destabilizes the protein. Our findings provide a cautionary tale for clinicians who elect to “suppress” infections in prosthetic joints and offer novel insights into the interaction of β-lactam antibiotics with low-affinity PBP4. These insights will help inform future efforts to develop therapeutics capable of inhibiting clinical enterococcal strains.
- Open Access
- 1 May 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (21) , 7916-7929
An N-terminally truncated form of cyclic GMP–dependent protein kinase Iα (PKG Iα) is monomeric and autoinhibited and provides a model for activation
- 1 May 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (21) , 7916-7929
Open AccessAn N-terminally truncated form of cyclic GMP–dependent protein kinase Iα (PKG Iα) is monomeric and autoinhibited and provides a model for activation
- 1 December 2015
- Published by Elsevier in Chemistry & Biology
- Vol. 22 (12) , 1653-1661
Synthetic Peptides as cGMP-Independent Activators of cGMP-Dependent Protein Kinase Iα
- 1 December 2015
- Published by Elsevier in Chemistry & Biology
- Vol. 22 (12) , 1653-1661
Synthetic Peptides as cGMP-Independent Activators of cGMP-Dependent Protein Kinase Iα
- Top Cited Papers
- 6 May 2014
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 7 (324) , ra41
Chloride Sensing by WNK1 Involves Inhibition of Autophosphorylation
Structural analysis reveals how chloride inhibits the activation of a kinase implicated in hypertension.
- 6 May 2014
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 7 (324) , ra41
Top Cited PapersChloride Sensing by WNK1 Involves Inhibition of Autophosphorylation
Structural analysis reveals how chloride inhibits the activation of a kinase implicated in hypertension.